Plain-English translation of NCT06207799 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to help people with newly diagnosed, aggressive multiple myeloma get better results from stem cell transplant. The medication is given before transplant to shrink cancer cells, and then again afterward to help prevent the cancer from coming back. The goal is to help more patients achieve a state where no cancer cells can be detected for at least a year or longer.
Multiple myeloma is an aggressive blood cancer that can come back even after stem cell transplant. This trial is testing whether the new treatment can improve transplant outcomes and help keep the cancer away longer by targeting cancer cells at multiple stages of treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication as part of a series of treatments: first, as induction therapy to shrink cancer cells; then during a stem cell collection and transplant process; and finally as maintenance therapy after transplant. Your participation will span many months, involving frequent clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working. The trial team will follow you closely to watch for side effects and to measure whether your cancer stays in remission.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States